Analysts expect Nurix Therapeutics, Inc. to report revenue of 39.54 M for Q4 26, against a range of 36.62 M to 42.46 M. The most recent reported quarter, Q3 26, came in at 673.06 M , in line with the 25.86 M consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 13.28 M | 18.45 M | 44.06 M | 7.89 M | 13.58 M | 6.25 M | 9.04 M | 673.06 M | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 14.67 M | 12.82 M | 19.88 M | 16.45 M | 14.72 M | 14.36 M | 15.60 M | 27.68 M | 42.46 M | 16.53 M | 15.93 M | 18.14 M | 25.56 M | 31.33 M | 38.87 M | 112.01 M | |||||||||
| Low Estimate | 12.39 M | 11.66 M | 16.32 M | 13.93 M | 13.76 M | 12.16 M | 13.74 M | 24.03 M | 36.62 M | 13.84 M | 13.49 M | 16.16 M | 22.46 M | 29.31 M | 36.20 M | 103.73 M | |||||||||
| Consensus Estimate | 13.53 M | 12.24 M | 18.10 M | 15.19 M | 14.24 M | 13.26 M | 14.67 M | 25.86 M | 39.54 M | 15.19 M | 14.71 M | 17.15 M | 24.01 M | 30.32 M | 37.54 M | 107.87 M |
Analysts expect Nurix Therapeutics, Inc. to report earnings per share of -0.40 for Q4 26, against a range of -0.43 to -0.37. The most recent reported quarter, Q3 26, came in at 4.73, a 929.8% beat against the -0.57 consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.75 | -0.67 | -0.52 | -1.03 | -0.82 | -0.79 | -0.81 | 4.73 | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | -0.66 | -0.77 | -0.70 | -0.80 | -0.79 | -0.78 | -0.71 | -0.54 | -0.37 | -0.50 | -0.54 | -0.50 | -1.72 | -0.37 | -0.05 | 0.91 | |||||||||
| Low Estimate | -0.78 | -0.83 | -0.78 | -0.88 | -0.89 | -0.84 | -0.79 | -0.60 | -0.43 | -0.60 | -0.62 | -0.58 | -1.86 | -0.41 | -0.05 | 0.75 | |||||||||
| Consensus Estimate | -0.72 | -0.80 | -0.74 | -0.84 | -0.84 | -0.81 | -0.75 | -0.57 | -0.40 | -0.55 | -0.58 | -0.54 | -1.79 | -0.39 | -0.05 | 0.83 |
Pull Wall Street consensus for Nurix Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=NRIX&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "NRIX", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=NRIX&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();